Investment Rating - The investment rating for the company is upgraded to "Accumulate" [1] Core Views - The company's short-term performance is under pressure due to factors such as inventory adjustments and price changes, but long-term growth is expected to be driven by the launch of new products [8] - The company is a global leader in cosmetic raw materials, and while 2024's performance is affected by the downstream inventory cycle, the penetration of new sunscreen agents is a long-term industry trend [8] - The company has sufficient capacity reserves and is actively expanding production, particularly in Malaysia, which will enhance its risk resistance and internationalization [8] Financial Summary - In 2024, the company is projected to achieve total revenue of 22.76 billion yuan, a decrease of 5.16% year-on-year, and a net profit attributable to shareholders of 5.62 billion yuan, down 23.33% [8] - The gross margin for 2024 and Q1 2025 is expected to be 44.40% and 34.04%, respectively, reflecting a decline due to price adjustments in sunscreen products [8] - The company's earnings per share (EPS) for 2024 is projected at 1.66 yuan, with a price-to-earnings (P/E) ratio of 12.61 [1][9]

关于南京科思化学股份有限公司 申请向不特定对象发行可转换公司债券的 审核问询函之回复报告 【天衡专字 (2023) 00017 号】 天衡会计师事务所 (特殊普通合伙) 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行查询 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行查询的 南京科思化学股份有限公司 审核问询函之回复报告 关于南京科思化学股份有限公司 申请向不特定对象发行可转换公司债券的 审核问询函之回复报告 天衡专字(2023)00017 号 深圳证券交易所: 贵所于 2022年 11月 9 日下发的《关于南京科思化学股份有限公司申请向不特定对象 发行可转换公司债券的审核间询函》(审核函〔2022〕020268 号)(以下简称"审核问询 函")已收悉。天衡会计师事务所(特殊普通合伙)作为科思股份的申报会计师(以下简称 "会计师"),就审核问询函中需会计师核查的相关问题进行了认真核查与落实。现将有关 情况汇报说明如下: 问题二 报告期内, 发行人境外收入分别为 98,191.57 万元、88 ...